ENOV vs SN.L
ENOV: A medical technology company providing a comprehensive continuum of orthopedic care, from injury prevention and rehabilitation products to surgical reconstructive implants. SN.L: A global medical technology leader focused on restoring patient mobility through advanced orthopedic, sports medicine, and wound care solutions.
Side-by-side fundamentals
| Metric | ENOV | SN.L | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $26.06 | £10.74 | |
| Market cap as of 2026-08-24 | $1.5B | n/a | |
| PEG as of 2026-08-24 | -0.05 | n/a | |
| Net margin as of 2026-08-24 | -48.0% | n/a | |
| Gross margin as of 2026-08-24 | +61.4% | n/a | |
| Operating margin as of 2026-08-24 | -45.1% | n/a | |
| ROE as of 2026-08-24 | -68.2% | n/a | |
| ROA as of 2026-08-24 | -27.8% | n/a | |
| Debt / equity as of 2026-08-24 | 0.87 | n/a | |
| Revenue growth (YoY) as of 2026-08-24 | +4.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +12.9% | n/a | |
| Beta as of 2026-08-24 | 1.47 | n/a | |
| 1-year return as of 2026-08-21 close | -11.7% | -22.8% | ENOV higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.